Physician profile
Naima A Dillard
NPI 1093779191
$1,894.50
in general payments reported to CMS, 2019-2025
22 companies · $132 in 2025
The $132 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2020: $120 · 2021: $482 · 2022: $268 · 2023: $353 · 2024: $399 · 2025: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $883.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $806.01 | 2019-2025 | Lo Loestrin Fe, Orilissa |
| Astellas Pharma US INC | $158.45 | 2024-2025 | Veozah |
| Myriad Women'S Health, INC. | $135.76 | 2023 | Myrisk |
| Evofem Biosciences, INC. | $114.72 | 2021-2025 | Phexxi, Solosec, Phexx |
| Hologic Sales and Service, LLC | $108.17 | 2024-2025 | Coolseal Generator, Myosure Tissue Removal Device, Fetal Fibronectin Enzyme Immunoassay |
| Sumitomo Pharma America, INC. | $76.43 | 2023-2024 | Myfembree |
| Avion Pharmaceuticals | $65.01 | 2019-2021 | |
| Therapeuticsmd, INC. | $63.94 | 2019-2022 | |
| Daiichi Sankyo INC. | $50.37 | 2021-2023 | Injectafer |
| Mayne Pharma Commercial LLC | $44.64 | 2022-2023 | |
| Myovant Sciences INC. | $44.12 | 2021-2022 | |
| Pfizer INC. | $42.84 | 2022-2024 | |
| Allergan, INC. | $36.12 | 2019-2020 | |
| Aspira Women'S Health INC | $35.64 | 2022-2024 | Ova1 |
| Biogen, INC. | $28.05 | 2025 | Zurzuvae |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Meditrina | $15.50 | 2024 | |
| Shield Therapeutics INC | $14.92 | 2024 | |
| Mylan Pharmaceuticals INC. | $14.37 | 2022 | |
| Sanofi Pasteur INC. | $13.58 | 2025 | |
| Coopersurgical, INC. | $13.22 | 2020 | |
| Merck Sharp & Dohme LLC | $12.64 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naima Dillard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.